The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
Three major drug middlemen needlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 ...
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback